Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women

Stanford University School of Medicine, Stanford, CA, USA.
Diabetes Obesity and Metabolism (Impact Factor: 5.46). 10/2006; 8(5):538-54. DOI: 10.1111/j.1463-1326.2005.00545.x
Source: PubMed

ABSTRACT To quantify the effects of hormone-replacement therapy (HRT) on components of the metabolic syndrome in postmenopausal women.
Comprehensive searches of electronic databases were performed from April 1966 to October 2004. We included randomized controlled trials that were of at least 8 weeks duration and evaluated the effect of HRT on metabolic, inflammatory or thrombotic components. Insulin resistance was calculated by homeostasis model assessment (HOMA-IR). Subgroup analysis evaluated the effects for transdermal and oral treatment and for diabetic and non-diabetic women.
Pooled results of 107 trials showed that HRT reduced abdominal fat [-6.8% (CI, -11.8 to -1.9%)], HOMA-IR [-12.9% (CI, -17.1 to -8.6%)] and new-onset diabetes [relative risk 0.7 (CI, 0.6-0.9)] in women without diabetes. In women with diabetes, HRT reduced fasting glucose [-11.5% (CI, -18.0 to -5.1%)] and HOMA-IR [-35.8% (CI, -51.7 to -19.8%)]. HRT also reduced low-density lipoprotein/high-density lipoprotein cholesterol ratio [-15.7% (CI, -18.0 to -13.5%)], lipoprotein(a) [Lp(a)] [-25.0% [CI, -32.9 to -17.1%)], mean blood pressure [-1.7% (CI, -2.9 to -0.5%)], E-selectin [-17.3% (CI, -22.4 to -12.1%)], fibrinogen [-5.5% (CI, -7.8 to -3.2%)] and plasminogen activator inhibitor-1 [-25.1% (CI, -33.6 to -15.5%)]. Oral agents produced larger beneficial effects than transdermal agents, but increased C-reactive protein (CRP) [37.6% (CI, 17.4-61.3%)] and decreased protein S [-8.6% CI, -13.1 to -4.1%)], while transdermal agents had no effect.
HRT reduces abdominal obesity, insulin resistance, new-onset diabetes, lipids, blood pressure, adhesion molecules and procoagulant factors in women without diabetes and reduced insulin resistance and fasting glucose in women with diabetes. Oral agents adversely affected CRP and protein S, while transdermal agents had no effects.

Download full-text


Available from: Shelley R Salpeter, Jun 15, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Women of African ancestry, particularly those living in industrialized countries, experience a disproportionately higher prevalence of type 2 diabetes (T2D) compared to their white counterparts. Similarly, obesity and insulin resistance, which are major risk factors for T2D, are greater in black compared to white women. The exact mechanisms underlying these phenomena are not known. This paper will focus on the role of adipose tissue biology. Firstly, the characteristic body fat distribution of women of African ancestry will be discussed, followed by the depot-specific associations with insulin resistance. Factors involved in adipose tissue biology and their relation to insulin sensitivity will then be explored, including the role of sex hormones, glucocorticoid metabolism, lipolysis and adipogenesis, and their consequent effects on adipose tissue hypoxia, oxidative stress, and inflammation. Finally the role of ectopic fat deposition will be discussed. The paper proposes directions for future research, in particular highlighting the need for longitudinal and/or intervention studies to better understand the mechanisms underlying the high prevalence of insulin resistance and T2D in women of African ancestry.
    Journal of obesity 01/2013; 2013:952916. DOI:10.1155/2013/952916
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Metabolic syndrome describes the presence of a cluster of factors that are associated with increased risk of diabetes and cardiovascular disease. The prevalence of the metabolic syndrome is between 10 and 25% of adults across the world. In 2009 a consensus definition of the syndrome was agreed, although the value of defining and identifying the presence of metabolic syndrome still creates controversy. The main advantage of identifying the presence of the metabolic syndrome is in clinical practice, to encourage lifestyle change among people whose individual cardiometabolic risk factors do not meet established thresholds for pharmacological invention. There is extensive evidence that lifestyle change can reduce the incidence of diabetes, but challenges remain in supporting adoption of lifestyle change in populations. Although there is limited evidence, it is anticipated that lifestyle change among people with metabolic syndrome could also contribute to the reduction of risk of cardiovascular disease and conditions associated with the metabolic syndrome including sleep apnea, some cancers, non-alcoholic fatty liver disease and possibly even mental health conditions. The current approach to defining the metabolic syndrome is of limited value for estimating an individual's risk of cardiovascular disease, although the use of the components of the metabolic syndrome as continuous variables may prove valuable and is a topic of current research. This chapter describes the definitions, factors and consequences associated with the metabolic syndrome and the chapter also introduces subsequent chapters in the context of the epidemiology of the metabolic syndrome.
    The Metabolic Syndrome, Second Edition, 06/2011: pages 1 - 18; , ISBN: 9781444347319
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study investigated the effects of indole-3-carbinol (I3C), a cruciferous vegetable derivative, on obesity and its associated factors in high-fat-diet-induced obese (DIO) mice. Eighteen male C57BL/6 mice were randomly assigned to one of three groups: basal, high fat (HF), and HF + 5 mg/kg of I3C intraperitoneally (HFI). After 12 wk of treatment, obesity-associated factors, including body weight, organ weight, serum concentrations of glucose, triacylglycerol, insulin, and adipokines, and macrophage accumulation and lipid metabolism-associated factors in epididymal adipose tissue were measured. Body weight and epididymal adipose tissue weight were greater (P < 0.01), and adipocytes were larger in the HF group than in the basal and HFI groups. Compared with the HF group, the HFI group had improved glucose tolerance, a higher serum adiponectin concentration, lower serum glucose, triacylglycerol, insulin, and leptin concentrations, and less F4/80 expression in epididymal adipose tissue (P < 0.001). Furthermore, I3C treatment decreased acetyl coenzyme A carboxylase mRNA expression (P < 0.05) and increased peroxisome proliferator-activated receptor-γ protein expression (P < 0.05) in epididymal adipose tissue of DIO mice. The I3C treatment decreased body weight and fat accumulation and infiltrated macrophages in epididymal adipose tissue of DIO mice, and these reductions were associated with improved glucose tolerance and with modulated expression of adipokines and lipogenic-associated gene products, including acetyl coenzyme A carboxylase and peroxisome proliferator-activated receptor-γ.
    Nutrition 04/2011; 27(4):463-70. DOI:10.1016/j.nut.2010.09.006 · 3.05 Impact Factor

Similar Publications